Plain-English translation of NCT07630168 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether the time of day you receive anti-PD-1 or PD-L1 inhibitor immunotherapy affects how well it treats your cancer. Researchers know these medications work by boosting your immune system to fight cancer, but they want to learn if giving the treatment in the morning versus afternoon makes a difference in survival and treatment response. You'll be randomly assigned to receive your infusions either before noon or in the afternoon, and researchers will follow your health for up to 2 years.
While immunotherapy has helped many cancer patients, doctors want to understand whether timing of treatment—which relates to natural daily cycles in your body—could improve outcomes. This knowledge could help doctors give this treatment at the best possible time for each patient.
You likely qualify if…
You likely don't qualify if…
If you join, you'll continue receiving your standard immunotherapy treatment as planned, but your infusions will be scheduled either in the morning (before 12:00 PM) or afternoon (after 3:00 PM) based on random assignment. All your regular cancer care—imaging scans, blood tests, and doctor visits—will continue as usual. Researchers will collect information about your treatment response and health outcomes from your medical records for up to 2 years; you won't need extra visits or procedures beyond your normal cancer care.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
United States